Prevalence of Plasmodium falciparum haplotypes associated with resistance to sulfadoxine-pyrimethamine and amodiaquine before and after upscaling of seasonal malaria chemoprevention in seven African countries: a genomic surveillance study.


Journal

The Lancet. Infectious diseases
ISSN: 1474-4457
Titre abrégé: Lancet Infect Dis
Pays: United States
ID NLM: 101130150

Informations de publication

Date de publication:
03 2023
Historique:
received: 20 06 2022
revised: 08 08 2022
accepted: 02 09 2022
pubmed: 4 11 2022
medline: 3 3 2023
entrez: 3 11 2022
Statut: ppublish

Résumé

Seasonal malaria chemoprevention is used in 13 countries in the Sahel region of Africa to prevent malaria in children younger than 5 years. Resistance of Plasmodium falciparum to seasonal malaria chemoprevention drugs across the region is a potential threat to this intervention. Between December, 2015, and March, 2016, and between December, 2017, and March, 2018, immediately following the 2015 and 2017 malaria transmission seasons, community surveys were done among children younger than 5 years and individuals aged 10-30 years in districts implementing seasonal malaria chemoprevention with sulfadoxine-pyrimethamine and amodiaquine in Burkina Faso, Chad, Guinea, Mali, Nigeria, Niger and The Gambia. Dried blood samples were collected and tested for P falciparum DNA by PCR. Resistance-associated haplotypes of the P falciparum genes crt, mdr1, dhfr, and dhps were identified by quantitative PCR and sequencing of isolates from the collected samples, and survey-weighted prevalence and prevalence ratio between the first and second surveys were estimated for each variant. 5130 (17·5%) of 29 274 samples from 2016 and 2176 (7·6%) of 28 546 samples from 2018 were positive for P falciparum on quantitative PCR. Among children younger than 5 years, parasite carriage decreased from 2844 of 14 345 samples (19·8% [95% CI 19·2-20·5]) in 2016 to 801 of 14 019 samples (5·7% [5·3-6·1]) in 2018 (prevalence ratio 0·27 [95% CI 0·24-0·31], p<0·0001). Genotyping found no consistent evidence of increasing prevalence of amodiaquine resistance-associated variants of crt and mdr1 between 2016 and 2018. The dhfr haplotype IRN (consisting of 51Ile-59Arg-108Asn) was common at both survey timepoints, but the dhps haplotype ISGEAA (431Ile-436Ser-437Gly-540Glu-581Ala-613Ala), crucial for resistance to sulfadoxine-pyrimethamine, was always rare. Parasites carrying amodiaquine resistance-associated variants of both crt and mdr1 together with dhfr IRN and dhps ISGEAA occurred in 0·05% of isolates. The emerging dhps haplotype VAGKGS (431Val-436Ala-437Gly-540Lys-581Gly-613Ser) was present in four countries. In seven African countries, evidence of a significant reduction in parasite carriage among children receiving seasonal malaria chemoprevention was found 2 years after intervention scale-up. Combined resistance-associated haplotypes remained rare, and seasonal malaria chemoprevention with sulfadoxine-pyrimethamine and amodiaquine is expected to retain effectiveness. The threat of future erosion of effectiveness due to dhps variant haplotypes requires further monitoring. Unitaid.

Sections du résumé

BACKGROUND
Seasonal malaria chemoprevention is used in 13 countries in the Sahel region of Africa to prevent malaria in children younger than 5 years. Resistance of Plasmodium falciparum to seasonal malaria chemoprevention drugs across the region is a potential threat to this intervention.
METHODS
Between December, 2015, and March, 2016, and between December, 2017, and March, 2018, immediately following the 2015 and 2017 malaria transmission seasons, community surveys were done among children younger than 5 years and individuals aged 10-30 years in districts implementing seasonal malaria chemoprevention with sulfadoxine-pyrimethamine and amodiaquine in Burkina Faso, Chad, Guinea, Mali, Nigeria, Niger and The Gambia. Dried blood samples were collected and tested for P falciparum DNA by PCR. Resistance-associated haplotypes of the P falciparum genes crt, mdr1, dhfr, and dhps were identified by quantitative PCR and sequencing of isolates from the collected samples, and survey-weighted prevalence and prevalence ratio between the first and second surveys were estimated for each variant.
FINDINGS
5130 (17·5%) of 29 274 samples from 2016 and 2176 (7·6%) of 28 546 samples from 2018 were positive for P falciparum on quantitative PCR. Among children younger than 5 years, parasite carriage decreased from 2844 of 14 345 samples (19·8% [95% CI 19·2-20·5]) in 2016 to 801 of 14 019 samples (5·7% [5·3-6·1]) in 2018 (prevalence ratio 0·27 [95% CI 0·24-0·31], p<0·0001). Genotyping found no consistent evidence of increasing prevalence of amodiaquine resistance-associated variants of crt and mdr1 between 2016 and 2018. The dhfr haplotype IRN (consisting of 51Ile-59Arg-108Asn) was common at both survey timepoints, but the dhps haplotype ISGEAA (431Ile-436Ser-437Gly-540Glu-581Ala-613Ala), crucial for resistance to sulfadoxine-pyrimethamine, was always rare. Parasites carrying amodiaquine resistance-associated variants of both crt and mdr1 together with dhfr IRN and dhps ISGEAA occurred in 0·05% of isolates. The emerging dhps haplotype VAGKGS (431Val-436Ala-437Gly-540Lys-581Gly-613Ser) was present in four countries.
INTERPRETATION
In seven African countries, evidence of a significant reduction in parasite carriage among children receiving seasonal malaria chemoprevention was found 2 years after intervention scale-up. Combined resistance-associated haplotypes remained rare, and seasonal malaria chemoprevention with sulfadoxine-pyrimethamine and amodiaquine is expected to retain effectiveness. The threat of future erosion of effectiveness due to dhps variant haplotypes requires further monitoring.
FUNDING
Unitaid.

Identifiants

pubmed: 36328000
pii: S1473-3099(22)00593-X
doi: 10.1016/S1473-3099(22)00593-X
pii:
doi:

Substances chimiques

fanasil, pyrimethamine drug combination 37338-39-9
Amodiaquine 220236ED28
Antimalarials 0
Pyrimethamine Z3614QOX8W
Sulfadoxine 88463U4SM5
Drug Combinations 0
Tetrahydrofolate Dehydrogenase EC 1.5.1.3

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

361-370

Subventions

Organisme : World Health Organization
ID : 001
Pays : International
Organisme : Medical Research Council
ID : MR/T016124/1
Pays : United Kingdom

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2023 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests We declare no competing interests.

Auteurs

Khalid B Beshir (KB)

Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK.

Julian Muwanguzi (J)

Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK.

Johanna Nader (J)

Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK; Department of Genetics and Bioinformatics, Division of Health Data and Digitalization, Norwegian Institute of Public Health, Oslo, Norway.

Raoul Mansukhani (R)

Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK.

Aliou Traore (A)

Malaria Research and Training Centre, University of Bamako, Bamako, Mali.

Kadidja Gamougam (K)

Centre de Support en Santé Internationale, N'Djamena, Chad.

Sainey Ceesay (S)

Medical Research Council Laboratories, London School of Hygiene & Tropical Medicine, Fajara, The Gambia.

Thomas Bazie (T)

Institute of Health Science Research, Bobo-Dioulasso, Burkina Faso.

Fassou Kolie (F)

Université Gamal Abdel Nasser de Conakry, Conakry, Guinea.

Mahaman M Lamine (MM)

Centre de Recherche Médecale et Sanitaire, Niamey, Niger.

Matt Cairns (M)

Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK.

Paul Snell (P)

Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK.

Susana Scott (S)

Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK.

Abdoulaye Diallo (A)

Université Cheikh Anta Diop, Dakar, Senegal.

Corinne S Merle (CS)

Special Programme for Research & Training in Tropical Diseases, WHO, Geneva, Switzerland.

Jean Louis NDiaye (JL)

Université Cheikh Anta Diop, Dakar, Senegal.

Lanto Razafindralambo (L)

Catholic Relief Services, Dakar, Senegal.

Diego Moroso (D)

Malaria Consortium, Kampala, Uganda; UK Foreign, Commonwealth, & Development Office, Lagos, Nigeria.

Jean-Bosco Ouedraogo (JB)

Institute of Health Science Research, Bobo-Dioulasso, Burkina Faso.

Issaka Zongo (I)

Institute of Health Science Research, Bobo-Dioulasso, Burkina Faso.

Hamit Kessely (H)

Centre de Support en Santé Internationale, N'Djamena, Chad.

Daugla Doumagoum (D)

Centre de Support en Santé Internationale, N'Djamena, Chad.

Kalifa Bojang (K)

Medical Research Council Laboratories, London School of Hygiene & Tropical Medicine, Fajara, The Gambia.

Serign Ceesay (S)

Medical Research Council Laboratories, London School of Hygiene & Tropical Medicine, Fajara, The Gambia.

Kovana Loua (K)

Université Gamal Abdel Nasser de Conakry, Conakry, Guinea.

Hamma Maiga (H)

Malaria Research and Training Centre, University of Bamako, Bamako, Mali.

Alassane Dicko (A)

Malaria Research and Training Centre, University of Bamako, Bamako, Mali.

Issaka Sagara (I)

Malaria Research and Training Centre, University of Bamako, Bamako, Mali.

Ibrahim M Laminou (IM)

Centre de Recherche Médecale et Sanitaire, Niamey, Niger.

Sonny Johnbull Ogboi (SJ)

Jedima International Health Consult, Lagos, Nigeria.

Tony Eloike (T)

Jedima International Health Consult, Lagos, Nigeria.

Paul Milligan (P)

Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK.

Colin J Sutherland (CJ)

Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK. Electronic address: colin.sutherland@lshtm.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH